Combination Therapy of GLP-1 RA and SGLT2i in Patients with Established Heart Failure: A Systematic Review and Meta-Analysis of Observational Studies.
Christopher Daniel Tristan, Irnizarifka Irnizarifka, Erlangga Masykur Kynaya et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effects of combination therapy with GLP-1 RA and SGLT2i compared to SGLT2i alone in patients with established heart failure. The analysis included eight cohorts totaling 75,833 patients. The combination therapy was associated with a 38% reduction in all-cause mortality (RR: 0.62) and a 26% reduction in all-cause hospitalization (RR: 0.89) over one year.
Key findings
- Combination therapy reduced all-cause mortality by 38% (RR: 0.62; p = 0.0014).
- There was a 26% reduction in all-cause hospitalization (RR: 0.89; p = 0.0012).
- Worsening heart failure risk decreased by 26% (RR: 0.74; p = 0.0001).
- LVEF improved by 3.83% (MD: 3.83%; p = 0.0397) with combination therapy.
Why it matters
The findings suggest that combining GLP-1 RA with SGLT2i may enhance clinical outcomes in heart failure patients, potentially leading to lower mortality and hospitalization rates. This could inform treatment strategies in managing heart failure.